Adrenocorticotropic Hormone Market
Number of pages: 100 | Report Format: PDF | Published date: March 02, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 1.33 billion |
|
Revenue Forecast in 2031 |
US$ 1.95 billion |
|
CAGR |
4.3% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Source, Application, End-user, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global adrenocorticotropic hormone market was valued at US$ 1.33 billion in 2022 and is expected to register a revenue CAGR of 4.3% to reach US$ 1.95 billion by 2031.
Adrenocorticotropic Hormone Market Fundamentals
The pituitary gland produces adrenocorticotropic hormone (ACTH). It plays a key role in regulating the body’s response to stress and controlling the production of other hormones, including cortisol. ACTH is typically used in medical practice to diagnose and treat conditions related to the adrenal gland, such as adrenal insufficiency and Cushing’s syndrome.
ACTH works by binding to receptors in the adrenal gland and stimulating the production of cortisol, a hormone that helps the body respond to stress. In some cases, ACTH levels may be elevated due to an underlying medical condition, such as a tumor in the pituitary gland. In other cases, ACTH may be used therapeutically to help regulate cortisol levels in patients with adrenal insufficiency or other conditions.
[567867]
Adrenocorticotropic Hormone Market Dynamics
the rising incidence of neurological disorders is the primary driver for the revenue growth of the global adrenocorticotropic hormone market. For instance, according to the Multiple Sclerosis International Federation’s report of September 2020, there are approximately 2.8 million individuals living with multiple sclerosis (MS) worldwide, which equates to 1 in every 3,000 individuals. Hormone replacement therapy is progressively used to treat hormonal imbalances caused by menopause, aging, and other factors. In certain cases, ACTH is a key component of hormone replacement therapy, driving the demand for adrenocorticotropic hormone globally.
The growing trend of personalized medicine is driving the demand for ACTH, as it is used in diagnosing and treating a range of adrenal gland disorders that require personalized treatment approaches. Moreover, a significant amount of investment is being made in the research and development of new treatments for adrenal gland disorders, which eventually leads to the development of new formulation and delivery methods of ACTH and helps in the market revenue growth.
However, alternative treatments are available for some of the conditions that ACTH treats, such as steroid medications, which are less expensive and more effective than ACTH. This factor can hamper the market revenue growth to some extent. Additionally, the high costs associated with research and development, the shortage of skilled professionals, and the side effects associated with the ACTH are some restraints impeding the overall market revenue growth.
Adrenocorticotropic Hormone Market Ecosystem
The global adrenocorticotropic hormone market is analyzed from four perspectives: source, application, end-user, and region.
Adrenocorticotropic Hormone Market by Source
[8567576]
Based on the source, the global adrenocorticotropic hormone market is segmented into natural ACTH and synthetic ACTH.
The synthetic ACTH segment dominated the market with the largest revenue share in 2022, as it can be easily synthesized from yeast or bacteria compared to natural ACTH. Synthetic ACTH, also known as cosyntropin, is an artificial version of the natural hormone produced by the anterior pituitary gland in the brain. Synthetic ACTH is produced by recombinant DNA technology, using genetically engineered bacteria or yeast to produce a peptide sequence identical to the biologically active portion of the natural hormone. Synthetic ACTH is primarily used for diagnostic purposes, specifically the ACTH stimulation test, which is used to evaluate the function of the adrenal gland. Synthetic ACTH is also used to treat conditions, such as infantile spasms and MS. It is injected into a muscle or vein and stimulate the adrenal gland to produce cortisol.
The natural ACTH segment is expected to be the fastest-growing segment during the forecast period, owing to the growing demand for naturally derived drugs in the market. Natural ACTH is a peptide hormone that stimulates the production and release of cortisol from adrenal glands. Natural ACTH is derived from the pituitary glands of cattle or pigs through a complex extraction and purification process. The purified hormone is then used for diagnostic purposes or as a medication for certain conditions. Natural ACTH is primarily used to diagnose and treat adrenal gland disorders, such as Addison’s disease, in which the adrenal glands do not produce sufficient cortisol. It can also differentiate between primary and secondary adrenal insufficiency, where primary adrenal insufficiency is caused by damage to the adrenal gland, and secondary adrenal insufficiency is caused due to a lack of ACTH production by the pituitary gland. These factors are attributed to the revenue growth of the natural source ACTH segment.
Adrenocorticotropic Hormone Market by Application
Based on the application, the global adrenocorticotropic hormone market is segmented into neurology, rheumatology, ophthalmology, nephrotic syndrome, and others.
The neurology segment dominated the market with the largest revenue share in 2022, attributed to its widespread usage in treating neurological disorders, such as infantile spasms and MS, which is a chronic autoimmune disease that affects the central nervous system. In MS, the immune system attacks and damages the myelin sheath surrounding and protecting nerve fibers, causing symptoms such as muscle weakness, vision loss, and cognitive impairment. ACTH is used to treat MS to reduce inflammation in the central nervous system and slow disease progression. ACTH is administered to patients with neurological disorders via injection into a muscle or vein. It works by stimulating the adrenal gland to produce cortisol, which has anti-inflammatory and immunosuppressive effects that can help to reduce inflammation and seizure activity in the brain. These factors contribute to the revenue growth of the neurology segment.
The nephrotic syndrome segment is expected to be the fastest-growing segment during the forecast period, as ACTH is being heavily explored in treating nephrotic syndrome. Nephrotic syndrome is a kidney disorder characterized by excessive protein loss via the urine, resulting in edema (swelling) and an increased risk of infection. Nephrotic syndrome can be caused due to various underlying conditions, including membranous nephropathy, minimal change disease, and focal segmental glomerulosclerosis. ACTH has been used in treating nephrotic syndrome, as it has anti-inflammatory and immunomodulatory effects that can help reduce proteinuria (excess protein in urine) and improve kidney function. ACTH is commonly used to treat nephrotic syndrome when other therapies, such as corticosteroids, are ineffective or ill-tolerated. These factors contribute to the revenue growth of the nephrotic syndrome segment growth.
Adrenocorticotropic Hormone Market by End-user
Based on the end-user, the global adrenocorticotropic hormone type market is segmented into hospitals and clinics, home care, and others.
The hospitals and clinics segment dominated the market with the largest revenue share in 2022, attributed to the large patient footfall and the presence of skilled healthcare professionals. Hospitals and clinics are healthcare facilities such as diagnosing, treating, and managing various medical conditions, including those requiring ACTH. Hospitals and clinics may use ACTH for various purposes, such as diagnostic testing, treatment of adrenal gland disorders, and treatment of neurological disorders, such as infantile spasms and MS. In addition, hospitals and clinics may also use ACTH to treat other conditions, such as nephrotic syndrome and rheumatoid arthritis (RA). ACTH products are usually administered via injection into a muscle or vein and may require special handling or administration techniques. Hospitals and clinics are equipped to provide these types of treatments. They have trained healthcare professionals who are familiar with the usage of ACTH and its potential side effects. Manufacturers of ACTH products may focus their marketing efforts on this segment by targeting healthcare professionals working in hospitals and clinics and providing educational materials and training programs to help healthcare professionals understand how to use ACTH safely and effectively. These overarching variables contribute to the hospital and clinic segment revenue growth.
The home care segment is expected to be the fastest-growing segment during the forecast period, owing to the ability of these services to provide a high level of patient convenience. Home care refers to medical care provided in the patient’s home rather than in a hospital or clinic. Home care may include various services, such as nursing care, physical therapy, and medication management. In recent years, there has been an increase in the number of patients who receive ACTH treatment in the home care setting. This is partly due to technological advances and the development of self-administration devices that allow patients to administer ACTH injections themselves under the supervision of a healthcare provider. Home care is a convenient option for many patients, particularly those who live far from medical facilities or have mobility issues, which make travel difficult. It can also be cost-effective for patients requiring frequent ACTH injections or other medications. These factors are expected to boost the home care segment’s development in the next few years.
Adrenocorticotropic Hormone Market by Region
Geographically, the global adrenocorticotropic hormone market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America dominated the global adrenocorticotropic hormone market with the largest revenue share in 2022, attributed to the fast adoption of technology and the rise in the incidence of neurological disorders. Additionally, companies across the region are continuously involved in research and development activities to launch new and more effective medicines for the treatment of adrenal gland disorders, contributing to the fastest revenue growth of the region. For instance, in January 2022, ANI Pharmaceuticals, Inc., a diversified biopharmaceutical company, announced the U.S. commercial availability of Purified Cortrophin Gel (Repository Corticotropin Injection USP) 80 U/mL. The commercial introduction of Cortrophin Gel, ACTH, commonly known as pure corticotropin, is directed by ANI’s newly created rare disease business unit. Cortrophin Gel is used to treat some chronic autoimmune conditions, such as acute exacerbations of MS and RA, as well as excess urine protein due to nephrotic syndrome.
Adrenocorticotropic Hormone Market Competitive Landscape
The prominent players operating in the global adrenocorticotropic hormone market are:
Adrenocorticotropic Hormone Market Strategic Developments
The global adrenocorticotropic hormone market is expected to reach US$ 1.33 billion by 2031.
The adrenocorticotropic hormone market is expected to register growth at a revenue CAGR of 4.3% during the forecast period from 2023 to 2031.
The rising incidence of neurological disorders, the growing trend of personalized medicines, and the increasing investments in research and development activities are driving revenue growth in the global adrenocorticotropic hormone market.
The high costs associated with research and development, shortage of skilled professionals, and side effects linked to ACTH restrict global market revenue growth to its full potential.
The prominent players operating in the global adrenocorticotropic hormone market include Ferring B.V., BCN Peptides S.A.U., Piramal Pharma Solutions, Viatris, Inc., and PolyPeptide Group.
*Insights on financial performance are subject to the availability of information in the public domain